<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.111017</article-id><article-id pub-id-type="publisher-id">ACM-39790</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210100000_31655252.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  心力衰竭患者血清中Neuronostatin水平及其与心衰严重程度的关系
  Serum Neurostatin Level in Patients with Heart Failure and Its Relationship with the Severity of Heart Failure
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>段</surname><given-names>传洲</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>戴</surname><given-names>红艳</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>管</surname><given-names>军</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>青岛市市立医院，保健四科，山东 青岛</addr-line></aff><aff id="aff2"><addr-line>潍坊医学院，临床医学院，山东 潍坊</addr-line></aff><aff id="aff4"><addr-line>青岛市市立医院，心内科，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>07</day><month>01</month><year>2021</year></pub-date><volume>11</volume><issue>01</issue><fpage>118</fpage><lpage>124</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：观察心力衰竭患者血清中neuronostatin水平及其与心衰严重程度的关系，探讨其临床意义。方法：选择其中射血分数降低的62例心衰患者作为实验组，并选取同期非心衰患者72例为对照组，采用酶联免疫吸附试验(ELISA)测定血清中neuronostatin水平。结果：心衰组血清中neuronostatin的水平较非心衰组明显升高，差异有统计学意义(p &lt; 0.05)；心功能III级neuronostatin的水平明显高于II级，心功能IV级neuronostatin的水平明显高于II级，差异均有统计学意义(p &lt; 0.05)；经Spearman相关分析，心衰组NST的水平与不同心功能分级呈正相关(r = 0.649, p &lt; 0.05)；采用ROC曲线，neuronostatin诊断心力衰竭的AUC为0.944。结论：血清中NST的水平升高可能与心力衰竭的发生发展有关，且与心功能的分级呈正相关。
    Objective: To observe the serum neuronostatin level in patients with heart failure and its relationship with the severity of heart failure, and to explore its clinical significance. Methods: 62 patients with heart failure with reduced ejection fraction were selected as the experimental group, and 72 patients with non-heart failure during the same period were selected as the control group. The level of neuronostatin in serum was determined by enzyme-linked immunosorbent assay (ELISA). Results: The level of neuronostatin in the serum of the heart failure group was significantly higher than that of the non-heart failure group, and the difference was statistically significant (p &lt; 0.05); the level of neuronostatin in cardiac function grade III was significantly higher than that in grade II, and the level of neuronostatin grade IV in cardiac function was significantly higher than that in grade II, and the differences were statistically significant (p &lt; 0.05); Spearman correlation analysis showed that the level of NST in the heart failure group was positively correlated with different cardiac function classifications (r = 0.649, p &lt; 0.05); ROC curve was used, and the AUC of neuronostatin for diagnosing heart failure is 0.944. Conclusion: The increased level of NST in serum may be related to the occurrence and development of heart failure, and is positively related to the grade of heart function. 
  
 
</p></abstract><kwd-group><kwd>心力衰竭，Neuronostatin，神经肽, Heart Failure</kwd><kwd> Neuronostatin</kwd><kwd> Neuropeptide</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：观察心力衰竭患者血清中neuronostatin水平及其与心衰严重程度的关系，探讨其临床意义。方法：选择其中射血分数降低的62例心衰患者作为实验组，并选取同期非心衰患者72例为对照组，采用酶联免疫吸附试验(ELISA)测定血清中neuronostatin水平。结果：心衰组血清中neuronostatin的水平较非心衰组明显升高，差异有统计学意义(p &lt; 0.05)；心功能III级neuronostatin的水平明显高于II级，心功能IV级neuronostatin的水平明显高于II级，差异均有统计学意义(p &lt; 0.05)；经Spearman相关分析，心衰组NST的水平与不同心功能分级呈正相关(r = 0.649, p &lt; 0.05)；采用ROC曲线，neuronostatin诊断心力衰竭的AUC为0.944。结论：血清中NST的水平升高可能与心力衰竭的发生发展有关，且与心功能的分级呈正相关。</p></sec><sec id="s2"><title>关键词</title><p>心力衰竭，Neuronostatin，神经肽</p></sec><sec id="s3"><title>Serum Neurostatin Level in Patients with Heart Failure and Its Relationship with the Severity of Heart Failure<sup> </sup></title><p>Chuanzhou Duan<sup>1</sup>, Hongyan Dai<sup>2</sup>, Jun Guan<sup>3*</sup></p><p><sup>1</sup>Clinical Medical College, Weifang Medical University, Weifang Shandong</p><p><sup>2</sup>The Fourth Department of Health Care, Qingdao Municipal Hospital, Qingdao Shandong</p><p><sup>3</sup>Department of Cardiology, Qingdao Municipal Hospital, Qingdao Shandong</p><p><img src="//html.hanspub.org/file/17-1571838x5_hanspub.png" /></p><p>Received: Dec. 14<sup>th</sup>, 2020; accepted: Jan. 3<sup>rd</sup>, 2021; published: Jan. 18<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/17-1571838x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To observe the serum neuronostatin level in patients with heart failure and its relationship with the severity of heart failure, and to explore its clinical significance. Methods: 62 patients with heart failure with reduced ejection fraction were selected as the experimental group, and 72 patients with non-heart failure during the same period were selected as the control group. The level of neuronostatin in serum was determined by enzyme-linked immunosorbent assay (ELISA). Results: The level of neuronostatin in the serum of the heart failure group was significantly higher than that of the non-heart failure group, and the difference was statistically significant (p &lt; 0.05); the level of neuronostatin in cardiac function grade III was significantly higher than that in grade II, and the level of neuronostatin grade IV in cardiac function was significantly higher than that in grade II, and the differences were statistically significant (p &lt; 0.05); Spearman correlation analysis showed that the level of NST in the heart failure group was positively correlated with different cardiac function classifications (r = 0.649, p &lt; 0.05); ROC curve was used, and the AUC of neuronostatin for diagnosing heart failure is 0.944. Conclusion: The increased level of NST in serum may be related to the occurrence and development of heart failure, and is positively related to the grade of heart function.</p><p>Keywords:Heart Failure, Neuronostatin, Neuropeptide</p><disp-formula id="hanspub.39790-formula25"><graphic xlink:href="//html.hanspub.org/file/17-1571838x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/17-1571838x8_hanspub.png" /> <img src="//html.hanspub.org/file/17-1571838x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 前言</title><p>慢性心力衰竭是多种心脏疾病的终末期表现，此时患者心脏功能显著下降，多数伴有明显器质性改变，治疗难度大，预后也差 [<xref ref-type="bibr" rid="hanspub.39790-ref1">1</xref>]。2008年Samon等人基于进化保守序列以及可能的酶切位点进行生物学分析后，在生长抑素前体蛋白的N端预测到了另一个多肽序列，并从猪脾脏和胰腺中提纯到了内源性的多肽，取名为neuronostatin，神经抑素或神经生长抑素，简称NST [<xref ref-type="bibr" rid="hanspub.39790-ref2">2</xref>]。NST的C端是进行高度酰胺化的线性肽，与生长抑素的环状结构不同；NST也在胰腺、心肌等组织中广泛表达，虽然二者是由同一基因进行编码、同一前体蛋白加工修饰而成，二者在不同组织中的含量是不同的：NST在脾脏中最高，生长抑素在下丘脑中最高，表示二者存在不同的加工过程 [<xref ref-type="bibr" rid="hanspub.39790-ref2">2</xref>]。生长抑素能够抑制心脏收缩，与之相似，NST也能够抑制心脏收缩，但二者抑制心脏收缩的机制是不一样的 [<xref ref-type="bibr" rid="hanspub.39790-ref3">3</xref>]。多项动物实验证实NST能够抑制心肌细胞的收缩，但目前国内尚无心力衰竭患者血清NST水平的研究，因此，本研究的目的是初步探索心力衰竭患者血清中NST的水平及其临床意义，现报告如下，</p></sec><sec id="s6"><title>2. 资料与分析</title><sec id="s6_1"><title>2.1. 一般资料</title><p>选取自2019 年1月~2019年12月在青岛市市立医院东院收治住院的心力衰竭患者，选取其中射血分数降低的62例作为心衰组，并选取同期非心衰患者72例为对照组。纳入标准：1) 心力衰竭组疾病诊断参考《2018中国心力衰竭诊断标准和治疗指南》 [<xref ref-type="bibr" rid="hanspub.39790-ref4">4</xref>]；而心功能分级根据美国纽约心脏病学会(NYHA)心衰分级方案，分为II~IV级。2) 年龄40~90岁；排除标准：与炎症和免疫相关的疾病如溃疡性结肠炎、支气管哮喘、结缔组织病、系统性红斑狼疮、恶性肿瘤、糖尿病等以及使用蛋白、抗炎及免疫抑制剂等治疗者。收集患者的年龄、性别、身高、体重、高血压病史、糖尿病史、冠心病史和吸烟史等一般资料。并根据身高、体重计算BMI，其中高血压、糖尿病、冠心病的诊断是根据高血压、糖尿病、冠心病的诊断和治疗指南来判定的。本研究经医院伦理委员会批准。所有患者均签署知情同意书。</p></sec><sec id="s6_2"><title>2.2. 研究方法</title><p>所有患者均在入院后24 h内采集2份空腹静脉血。一份经离心、分离提取出血清，保存在−80℃冰箱中直至进行NST的测定；另一份送医院实验室行空腹血糖(fasting blood glucose, FBG)、三酰甘油(triacylglycerol, TG)、总胆固醇(total cholesterol, TC)、低密度脂蛋白(low-density lipoprotein, LDL)、高密度脂蛋白(high density lipoprotein, HDL)和N末端脑利钠肽前体(NT-proBNP)的测量。在住院当天有两名不参与实验的心脏超声专家进行心脏彩色多普勒超声检查，测量左室射血分数(left ventricular ejection fraction, LVEF)。血清中NST测定采用酶联免疫吸附试验(ELISA)法，试剂盒(货号：JM-0890H1) 购自江苏晶美生物科技有限公司，实验操作严格按照说明书。</p></sec><sec id="s6_3"><title>2.3. 统计方法</title><p>基线数据中正态分布的连续性变量用均数和标准差表示，采用两独立样本t检验进行统计分析；非正态分布的连续性变量用中位数和四分位数表示，采用两独立样本Wilcoxon U检验。NST和NT-proBNP在不同心衰组中水平比较采用方差分析，两两比较采用Bonferroni检验。NST和NT-proBNP指标和生化指标相关采用spearman相关进行分析。心衰组中NST和NT-proBNP指标与心衰严重程度分析也采用spearman相关分析。心衰相关危险因素分析采用二分类多因素logistic回归分析。采用ROC曲线探究NST和NT-proBNP指标和两者联合对心衰的预测，AUC及其95%CI代表各指标预测心衰的效果，约登指数 = 灵敏度 + 特异度 − 1，选择约登指数最大所对应的NST和NT-proBNP作为截断值。数据录入采用Excel2010，数据分析采用SPSS22.0均以p &lt; 0.05为差异有统计学意义。</p></sec></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. 心衰组与非心衰组一般资料比较</title><p>心力衰竭患者与非心衰患者相比在性别、BMI、HR、收缩压、LVEF、TC、FBG、HbA1C、NT-proBNP、NST、吸烟史、糖尿病史、冠心病史差异有统计学意义(p &lt; 0.05)。见表1。</p><table-wrap-group id="1"><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Comparison of general data of heart failure group and non-heart failure grou</title></caption><table-wrap id="1_1"><table><tbody><thead><tr><th align="center" valign="middle" >项目</th><th align="center" valign="middle" >心衰组(n = 62)</th><th align="center" valign="middle" >非心衰组(n = 72)</th><th align="center" valign="middle" >t/卡方</th><th align="center" valign="middle" >p</th></tr></thead><tr><td align="center" valign="middle" >年龄(岁)</td><td align="center" valign="middle" >73.306 &#177; 14.388</td><td align="center" valign="middle" >70.639 &#177; 8.943</td><td align="center" valign="middle" >1.265</td><td align="center" valign="middle" >0.209</td></tr><tr><td align="center" valign="middle" >Sex (F/M)</td><td align="center" valign="middle" >25/37</td><td align="center" valign="middle" >42/30</td><td align="center" valign="middle" >4.323</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >BMI (kg/m<sup>2</sup>)</td><td align="center" valign="middle" >24.325 &#177; 3.564</td><td align="center" valign="middle" >25.9965 &#177; 2.700</td><td align="center" valign="middle" >−3.082</td><td align="center" valign="middle" >0.003</td></tr><tr><td align="center" valign="middle" >HR(次/分)</td><td align="center" valign="middle" >76.435 &#177; 15.351</td><td align="center" valign="middle" >67.806 &#177; 9.606</td><td align="center" valign="middle" >3.828</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >收缩压(mmHg)</td><td align="center" valign="middle" >127.758 &#177; 20.025</td><td align="center" valign="middle" >135.417 &#177; 17.100</td><td align="center" valign="middle" >−2.388</td><td align="center" valign="middle" >0.018</td></tr><tr><td align="center" valign="middle" >舒张压(mmHg)</td><td align="center" valign="middle" >74.113 &#177; 14.859</td><td align="center" valign="middle" >72.806 &#177; 9.619</td><td align="center" valign="middle" >0.594</td><td align="center" valign="middle" >0.554</td></tr></tbody></table></table-wrap><table-wrap id="1_2"><table><tbody><thead><tr><th align="center" valign="middle" >LVEF (%)</th><th align="center" valign="middle" >28.548 &#177; 4.9012</th><th align="center" valign="middle" >59.125 &#177; 2.716</th><th align="center" valign="middle" >−43.684</th><th align="center" valign="middle" >&lt;0.001</th></tr></thead><tr><td align="center" valign="middle" >LDL (mmol/L)</td><td align="center" valign="middle" >2.279 &#177; 0.737</td><td align="center" valign="middle" >2.500 &#177; 0.7291</td><td align="center" valign="middle" >−1.738</td><td align="center" valign="middle" >0.085</td></tr><tr><td align="center" valign="middle" >TC (mmol/L)</td><td align="center" valign="middle" >3.825 &#177; 1.046</td><td align="center" valign="middle" >4.320 &#177; 1.0774</td><td align="center" valign="middle" >−2.687</td><td align="center" valign="middle" >0.008</td></tr><tr><td align="center" valign="middle" >HDL (mmol/L)</td><td align="center" valign="middle" >1.187 &#177; 0.662</td><td align="center" valign="middle" >1.206 &#177; 0.299</td><td align="center" valign="middle" >−0.202</td><td align="center" valign="middle" >0.841</td></tr><tr><td align="center" valign="middle" >FBG (mmol/L)</td><td align="center" valign="middle" >6.451 &#177; 2.214</td><td align="center" valign="middle" >5.441 &#177; 0.935</td><td align="center" valign="middle" >3.345</td><td align="center" valign="middle" >0.001</td></tr><tr><td align="center" valign="middle" >HbA1C (%)</td><td align="center" valign="middle" >6.453 &#177; 1.445</td><td align="center" valign="middle" >6.026 &#177; 0.889</td><td align="center" valign="middle" >2.022</td><td align="center" valign="middle" >0.046</td></tr><tr><td align="center" valign="middle" >NT-proBNP (mmol/L)</td><td align="center" valign="middle" >4272.010 (1651.908~8164.748)</td><td align="center" valign="middle" >117.670 (55.215~318.373)</td><td align="center" valign="middle" >−9.474</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >NST (pg/ml)</td><td align="center" valign="middle" >18.160 (12.293~25.058)</td><td align="center" valign="middle" >6.447 (5.273~8.783)</td><td align="center" valign="middle" >−8.840</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >吸烟史(是/否)</td><td align="center" valign="middle" >27/35</td><td align="center" valign="middle" >20/52</td><td align="center" valign="middle" >4.123</td><td align="center" valign="middle" >0.045</td></tr><tr><td align="center" valign="middle" >高血压史(是/否)</td><td align="center" valign="middle" >43/19</td><td align="center" valign="middle" >51/21</td><td align="center" valign="middle" >0.018</td><td align="center" valign="middle" >0.893</td></tr><tr><td align="center" valign="middle" >糖尿病史(是/否)</td><td align="center" valign="middle" >27/35</td><td align="center" valign="middle" >18/54</td><td align="center" valign="middle" >5/139</td><td align="center" valign="middle" >0.023</td></tr><tr><td align="center" valign="middle" >冠心病史(是/否)</td><td align="center" valign="middle" >43/19</td><td align="center" valign="middle" >36/36</td><td align="center" valign="middle" >5.157</td><td align="center" valign="middle" >0.023</td></tr></tbody></table></table-wrap></table-wrap-group><p>表1. 心衰组与非心衰组一般资料比较</p></sec><sec id="s7_2"><title>3.2. NST和NT-proBNP在不同心衰组中水平比较</title><p>非心衰组与心衰各级的NST、NT-proBNP不全相等，差异有统计学意义(p &lt; 0.01)。心衰组中心功能II级、心功能III级、心功能IV级的NST的含量依次增加，差异有统计学意义(p &lt; 0.05)。见表2。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Comparison of NST and NT-proBNP levels in different heart failure group</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >非心衰组</th><th align="center" valign="middle" >心功能II级</th><th align="center" valign="middle" >心功能III级</th><th align="center" valign="middle" >心功能IV级</th><th align="center" valign="middle" >F</th><th align="center" valign="middle" >p</th></tr></thead><tr><td align="center" valign="middle" >NST</td><td align="center" valign="middle" >6.45 (5.27~8.78)</td><td align="center" valign="middle" >12.42* (11.75~12.99)</td><td align="center" valign="middle" ><sup>a</sup>18.35* (16.17~23.60)</td><td align="center" valign="middle" ><sup>b</sup>21.32* (17.43~26.67)</td><td align="center" valign="middle" >100.815</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >NT-proBNP</td><td align="center" valign="middle" >117.67 (55.21~318.37)</td><td align="center" valign="middle" >1406.65* (1140.10~12991.51)</td><td align="center" valign="middle" >2889.24* (2185.35~3889.82)</td><td align="center" valign="middle" >5818.16* (226.05~8970.29)</td><td align="center" valign="middle" >94.408</td><td align="center" valign="middle" >&lt;0.001</td></tr></tbody></table></table-wrap><p>表2. NST和NT-proBNP在不同心衰组中水平比较</p><p>注：NST：*和非心衰组相比，P &lt; 0.001。<sup>a</sup>心功能III级与II级相比P &lt; 0.05，<sup>b</sup>心功能IV级与III级相比，P &lt; 0.05。</p></sec><sec id="s7_3"><title>3.3. Spearman相关分析</title><p>心衰组中心衰程度和NT-proBNP相关(p &lt; 0.05)，相关系数R = 0.658.心衰组中心衰程度和NST相关(p &lt; 0.05)，相关系数R = 0.649。见表3。</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Spearman correlation analysis of central failure degree and NT-proBNP, NST in heart failure grou</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >r</th><th align="center" valign="middle" >p</th></tr></thead><tr><td align="center" valign="middle" >NT-proBNP</td><td align="center" valign="middle" >0.658</td><td align="center" valign="middle" >0.004</td></tr><tr><td align="center" valign="middle" >NST</td><td align="center" valign="middle" >0.649</td><td align="center" valign="middle" >0.021</td></tr></tbody></table></table-wrap><p>表3. 心衰组中心衰程度和NT-proBNP、NST 的Spearman相关分析</p></sec><sec id="s7_4"><title>3.4. NT-proBNP和NST与各指标的Spearman相关分析</title><p>心力衰竭患者血清中NST的水平与LVEF呈负相关(r = −0.767, p &lt; 0.001)、与TG呈负相关(r = −0.307, p &lt; 0.001)、与NT-proBNP呈正相关(r = 0.694, p &lt; 0.001)、与HbA1C呈正相关(r = 0.179, p = 0.039)、与年龄呈正相关(r = 0.320, p &lt; 0.001)。见表4。</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Spearman correlation analysis of NT-proBNP and NST with each inde</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle"  colspan="2"  >NT-proBNP</th><th align="center" valign="middle"  colspan="2"  >NST</th></tr></thead><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >r</td><td align="center" valign="middle" >p</td><td align="center" valign="middle" >r</td><td align="center" valign="middle" >p</td></tr><tr><td align="center" valign="middle" >年龄</td><td align="center" valign="middle" >0.363</td><td align="center" valign="middle" >&lt;0.001</td><td align="center" valign="middle" >0.320</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >BMI</td><td align="center" valign="middle" >−0.242</td><td align="center" valign="middle" >0.005</td><td align="center" valign="middle" >−0.157</td><td align="center" valign="middle" >0.070</td></tr><tr><td align="center" valign="middle" >HR</td><td align="center" valign="middle" >0.315</td><td align="center" valign="middle" >&lt;0.001</td><td align="center" valign="middle" >0.193</td><td align="center" valign="middle" >0.025</td></tr><tr><td align="center" valign="middle" >收缩压</td><td align="center" valign="middle" >−0.182</td><td align="center" valign="middle" >0.035</td><td align="center" valign="middle" >−0.134</td><td align="center" valign="middle" >0.124</td></tr><tr><td align="center" valign="middle" >舒张压</td><td align="center" valign="middle" >0.031</td><td align="center" valign="middle" >0.721</td><td align="center" valign="middle" >−0.048</td><td align="center" valign="middle" >0.584</td></tr><tr><td align="center" valign="middle" >LVEF</td><td align="center" valign="middle" >−0.794</td><td align="center" valign="middle" >&lt;0.001</td><td align="center" valign="middle" >−0.767</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >LDL</td><td align="center" valign="middle" >−0.203</td><td align="center" valign="middle" >0.018</td><td align="center" valign="middle" >−0.060</td><td align="center" valign="middle" >0.487</td></tr><tr><td align="center" valign="middle" >TC</td><td align="center" valign="middle" >−0.221</td><td align="center" valign="middle" >0.010</td><td align="center" valign="middle" >−0.085</td><td align="center" valign="middle" >0.327</td></tr><tr><td align="center" valign="middle" >TG</td><td align="center" valign="middle" >−0.298</td><td align="center" valign="middle" >0.001</td><td align="center" valign="middle" >−0.307</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >HDL</td><td align="center" valign="middle" >−0.180</td><td align="center" valign="middle" >0.037</td><td align="center" valign="middle" >−0.116</td><td align="center" valign="middle" >0.183</td></tr><tr><td align="center" valign="middle" >FBG</td><td align="center" valign="middle" >0.061</td><td align="center" valign="middle" >0.487</td><td align="center" valign="middle" >0.114</td><td align="center" valign="middle" >0.188</td></tr><tr><td align="center" valign="middle" >HbA1C</td><td align="center" valign="middle" >0.179</td><td align="center" valign="middle" >0.039</td><td align="center" valign="middle" >0.179</td><td align="center" valign="middle" >0.039</td></tr><tr><td align="center" valign="middle" >NT-proBNP</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.694</td><td align="center" valign="middle" >&lt;0.001</td></tr></tbody></table></table-wrap><p>表4. NT-proBNP和NST与各指标的spearman相关分析</p></sec><sec id="s7_5"><title>3.5. 心衰相关危险因素的Logistic回归分析</title><p>心力衰竭患者血清中NT-proBNP (p = 0.021, OR = 1.006)、NST (p = 0.026, OR = 2.216)都是心衰的危险因素。见表5。</p><table-wrap id="table5" ><label><xref ref-type="table" rid="table5">Table 5</xref></label><caption><title> Logistic regression analysis of risk factors related to heart failur</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >B</th><th align="center" valign="middle" >S.E</th><th align="center" valign="middle" >wald</th><th align="center" valign="middle" >OR</th><th align="center" valign="middle" >LL</th><th align="center" valign="middle" >UL</th><th align="center" valign="middle" >P</th></tr></thead><tr><td align="center" valign="middle" >NT-proBNP</td><td align="center" valign="middle" >0.006</td><td align="center" valign="middle" >0.002</td><td align="center" valign="middle" >5.339</td><td align="center" valign="middle" >1.006</td><td align="center" valign="middle" >1.001</td><td align="center" valign="middle" >1.010</td><td align="center" valign="middle" >0.021</td></tr><tr><td align="center" valign="middle" >NST</td><td align="center" valign="middle" >0.796</td><td align="center" valign="middle" >0.358</td><td align="center" valign="middle" >4.946</td><td align="center" valign="middle" >2.216</td><td align="center" valign="middle" >1.099</td><td align="center" valign="middle" >4.469</td><td align="center" valign="middle" >0.026</td></tr><tr><td align="center" valign="middle" >年龄</td><td align="center" valign="middle" >−0.301</td><td align="center" valign="middle" >0.183</td><td align="center" valign="middle" >2.710</td><td align="center" valign="middle" >0.740</td><td align="center" valign="middle" >0.517</td><td align="center" valign="middle" >1.059</td><td align="center" valign="middle" >0.100</td></tr><tr><td align="center" valign="middle" >BMI</td><td align="center" valign="middle" >−0.407</td><td align="center" valign="middle" >0.355</td><td align="center" valign="middle" >1.315</td><td align="center" valign="middle" >0.666</td><td align="center" valign="middle" >0.332</td><td align="center" valign="middle" >1.335</td><td align="center" valign="middle" >0.251</td></tr><tr><td align="center" valign="middle" >TC</td><td align="center" valign="middle" >−2.696</td><td align="center" valign="middle" >1.879</td><td align="center" valign="middle" >2.059</td><td align="center" valign="middle" >0.067</td><td align="center" valign="middle" >0.002</td><td align="center" valign="middle" >2.681</td><td align="center" valign="middle" >0.151</td></tr><tr><td align="center" valign="middle" >收缩压</td><td align="center" valign="middle" >−0.103</td><td align="center" valign="middle" >0.076</td><td align="center" valign="middle" >1.865</td><td align="center" valign="middle" >0.902</td><td align="center" valign="middle" >0.777</td><td align="center" valign="middle" >1.046</td><td align="center" valign="middle" >0.172</td></tr><tr><td align="center" valign="middle" >FBG</td><td align="center" valign="middle" >1.722</td><td align="center" valign="middle" >1.279</td><td align="center" valign="middle" >1.813</td><td align="center" valign="middle" >5.595</td><td align="center" valign="middle" >0.456</td><td align="center" valign="middle" >68.586</td><td align="center" valign="middle" >0.178</td></tr><tr><td align="center" valign="middle" >HbA1C</td><td align="center" valign="middle" >1.885</td><td align="center" valign="middle" >1.230</td><td align="center" valign="middle" >2.351</td><td align="center" valign="middle" >6.588</td><td align="center" valign="middle" >0.592</td><td align="center" valign="middle" >73.344</td><td align="center" valign="middle" >0.125</td></tr><tr><td align="center" valign="middle" >冠心病史</td><td align="center" valign="middle" >−1.236</td><td align="center" valign="middle" >2.379</td><td align="center" valign="middle" >0.270</td><td align="center" valign="middle" >0.291</td><td align="center" valign="middle" >0.003</td><td align="center" valign="middle" >30.797</td><td align="center" valign="middle" >0.603</td></tr></tbody></table></table-wrap><p>表5. 心衰相关危险因素的Logistic回归分析</p></sec><sec id="s7_6"><title>3.6. NST、NT-proBNP、以及二者联合诊断心力衰竭价值</title><p>采用ROC曲线，根据NST、NT-proBNP、以及二者联合诊断建立心力衰竭ROC曲线。如图1。心衰患者血清中NST、NT-proBNP、以及二者联合AUC大于0.7，NST以9.872 pg/ml作为临界值，具有较好灵敏度和特异度。见表6。</p><p>图1. NST、NT-proBNP以及二者联合诊断心力衰竭ROC曲线</p></sec><sec id="s7_7"><title>3.7. ROC曲线下面积，灵敏度，特异度</title><p>心衰患者血清中NST、NT-proBNP、以及二者联合AUC大于0.7，有较高的诊断价值，NST以9.872 pg/ml作为临界值，具有较好灵敏度和特异度。见表6。</p><table-wrap id="table6" ><label><xref ref-type="table" rid="table6">Table 6</xref></label><caption><title> Area under ROC curve, sensitivity, specificit</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >AUC (95% CI)</th><th align="center" valign="middle" >灵敏度</th><th align="center" valign="middle" >特异性</th><th align="center" valign="middle" >Cutoff值</th></tr></thead><tr><td align="center" valign="middle" >NST (pg/ml)</td><td align="center" valign="middle" >0.944 (0.903~0.984)</td><td align="center" valign="middle" >0.952</td><td align="center" valign="middle" >0.917</td><td align="center" valign="middle" >9.872</td></tr><tr><td align="center" valign="middle" >NT-proBNP (mmolL)</td><td align="center" valign="middle" >0.976 (0.956~0.995)</td><td align="center" valign="middle" >0.952</td><td align="center" valign="middle" >0.903</td><td align="center" valign="middle" >849.665</td></tr><tr><td align="center" valign="middle" >联合</td><td align="center" valign="middle" >0.986 (0.972~0.999)</td><td align="center" valign="middle" >0.935</td><td align="center" valign="middle" >0.958</td><td align="center" valign="middle" >-</td></tr></tbody></table></table-wrap><p>表6. ROC曲线下面积，灵敏度，特异度</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>心力衰竭往往是多种心血管疾病终末的临床综合征，具有较高的发病率和病死率。其发病机制尚不完全清楚。NST能降低左心室舒张最低压(LVDP)，降低左室内压变化速率(dP/dt)，减慢心率，降低心肌细胞峰值缩短速度和细胞缩短及再延长最大速度，不会影响峰值缩短的时间(TPS)和90%的延长时间(TR90) [<xref ref-type="bibr" rid="hanspub.39790-ref5">5</xref>]，NST是利用蛋白激酶A和/或JNK依赖性机制抑制心脏收缩功能，这可能是二者在心脏上的膜受体不同造成的。我们可以得出NST可以导致心脏整体负性收缩反应。在离体灌流大鼠心脏和培养的原代心肌细胞中的实验中，单独使用NST输注对左心室(LV)收缩性能没有显著影响 [<xref ref-type="bibr" rid="hanspub.39790-ref6">6</xref>]。但是，我们发现联合应用神经生长抑素可显著减弱ET-1诱导的左室收缩反应，同时还发现二者联合应用会显著增强ET-1所诱导的p38MAPK磷酸化 [<xref ref-type="bibr" rid="hanspub.39790-ref6">6</xref>]。虽然机制还不完全清楚，但中心因素可能与肌丝对细胞内钙升高的脱敏有关 [<xref ref-type="bibr" rid="hanspub.39790-ref7">7</xref>]。有证据表明，肌浆网Ca<sup>2+</sup>处理不当会导致心肌收缩力降低 [<xref ref-type="bibr" rid="hanspub.39790-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.39790-ref9">9</xref>]。经过神经生长抑素治疗后，发现小鼠心肌细胞肌浆网Ca<sup>2+</sup>处理不当增加，这可能是肌浆网Ca<sup>2+</sup>负荷不佳而导致的细胞内Ca<sup>2+</sup>利用率降低 [<xref ref-type="bibr" rid="hanspub.39790-ref9">9</xref>]，以及改变了肌丝对Ca<sup>2+</sup>的敏感性有关 [<xref ref-type="bibr" rid="hanspub.39790-ref10">10</xref>]。从这些基础实验我们可以得出，NST抑制心肌细胞收缩的确切机制不清，但可以证实NST可以导致心脏整体负性收缩反应。</p><p>本实验数据显示，血清NST水平与血清NT-proBNP呈正相关，与左室射血分数(LVEF)呈负相关，心力衰竭患者不同心功能分级与NST水平存在相关性，随着心功能分级增加，血清NST水平逐渐升高，提示NST高表达慢性心力衰竭患者病情较重、预后较差。用SPSS.22软件进行ROC曲线分析，结果显示NST最佳相对表达水平临界值为9.78 pg/ml，灵敏度95.2%，特异性91.7%，AUC为0.944。</p><p>综上所述，加强NST水平的检测对心力衰竭的诊断以及对其心功能分级判定有一定的辅助性价值。NST可作为NT-proBNP等指标的重要补充手段，有潜力成为慢性心力衰竭的标志物，为慢性心力衰竭患者预后评估提供更多临床参考。考虑到本研究标本数量有限及国内外关于NST与心力衰竭的相关研究比较少，有关结论有待进一步扩大标本量再进行深入研究。</p></sec><sec id="s9"><title>文章引用</title><p>段传洲,戴红艳,管 军. 心力衰竭患者血清中Neuronostatin水平及其与心衰严重程度的关系Serum Neurostatin Level in Patients with Heart Failure and Its Relationship with the Severity of Heart Failure[J]. 临床医学进展, 2021, 11(01): 118-124. https://doi.org/10.12677/ACM.2021.111017</p></sec><sec id="s10"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.39790-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Eleuteri, E., Magno, F., Gnemmi, I., et al. (2009) Role of Oxidative and Nitrosative Stress Biomarkers in Chronic Heart Failure. Frontiers in Bioscience (Landmark Ed), 14, 2230-2237. &lt;br&gt;https://doi.org/10.2741/3375</mixed-citation></ref><ref id="hanspub.39790-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Samson, W.K., Zhang, J.V., Avsian-Kretchmer, O., et al. (2008) Neuronostatin Encoded by the Somatostatin Gene Regulates Neuronal, Cardiovascular, and Metabolic Functions. Journal of Biological Chemistry, 283, 1949-1959.  
&lt;br&gt;https://doi.org/10.1074/jbc.M804784200</mixed-citation></ref><ref id="hanspub.39790-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Hua, Y., Ma, H., Samson, W.K., et al. (2009) Neuronostatin Inhibits Cardiac Contractile Function via a Protein Kinase A- and JNK Dependent Mechanism in Murine Hearts. American Journal of Physiology—Regulatory, Integrative and Comparative Physiology, 297, R682-R689. &lt;br&gt;https://doi.org/10.1152/ajpregu.00196.2009</mixed-citation></ref><ref id="hanspub.39790-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">中华医学会心血管病学分会心力衰竭学组, 中国医师协会心力衰竭专业委员会, 中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南2018 [J]. 中华心血管病杂志, 2018, 46(10): 760-789.</mixed-citation></ref><ref id="hanspub.39790-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Hua, Y., Ma, H., Samson, W.K., et al. (2009) Neuronostatin Inhibits Cardiac Contractile Function via a Protein Kinase A- and JNK Dependent Mechanism in Murine Hearts. American Journal of Physiology—Regulatory, Integrative and Comparative Physiology, 297, B682-B689. &lt;br&gt;https://doi.org/10.1152/ajpregu.00196.2009</mixed-citation></ref><ref id="hanspub.39790-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Vainio, L., Perjes, A., Ryti, N., Magga, J., Alakoski, T., Serpi, R., Kaikkonen, L., Piuhola, J., Szokodi, I., Ruskoaho, H. and Kerkelä, R. (2012) Neuronostatin, A Novel Peptide Encoded by Somatostatin Gene, Regulates Cardiac Contractile Function and Cardiomyocyte Survival. Journal of Biological Chemistry, 287, 4572-4580.  
&lt;br&gt;https://doi.org/10.1074/jbc.M111.289215</mixed-citation></ref><ref id="hanspub.39790-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Liao, P., Wang, S.Q., Wang, S., Zheng, M., Zheng, M., Zhang, S.J., Cheng, H., Wang, Y. and Xiao, R.P. (2002) p38 Mitogen-Activated Protein Kinase Mediates a Negative Inotropic Effect in Cardiac Myocytes. Circulation Research, 90, 190-196. &lt;br&gt;https://doi.org/10.1161/hh0202.104220</mixed-citation></ref><ref id="hanspub.39790-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Hadri, L. and Hajjar, R.J. (2011) Calcium Cycling Proteins and Their Association with Heart Failure. Clinical Pharmacology &amp; Therapeutics, 90, 620-624. &lt;br&gt;https://doi.org/10.1038/clpt.2011.161</mixed-citation></ref><ref id="hanspub.39790-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Vafiadaki, E., Papalouka, V., Arvanitis, D.A., Kranias, E.G. and Sanoudou, D. (2009) The Role of SERCA2a/PLN Complex, Ca(2+) Homeostasis, and Anti-Apoptotic Proteins in Determining Cell Fate. Pflügers Archiv, 457, 687-700.  
&lt;br&gt;https://doi.org/10.1007/s00424-008-0506-5</mixed-citation></ref><ref id="hanspub.39790-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Van der Velden, J., Merkus, D., Klarenbeek, B.R., James, A.T., Boontje, N.M., Dekkers, D.H., Stienen, G.J., Lamers, J.M. and Duncker, D.J. (2004) Alterations in Myofilament Function Contribute to Left Ventricular Dysfunction in Pigs Early after Myocardial Infarction. Circulation Research, 95, e85-e95.  
&lt;br&gt;https://doi.org/10.1161/01.RES.0000149531.02904.09</mixed-citation></ref></ref-list></back></article>